Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: rimonabant + 0.26 + web  Related to the article below (Last Update: 8/5/2008)

This little drug went to market
Sydney Morning Herald, Australia - Jul 30, 2008
The drug, Rimonabant, is a cannabis-receptor antagonist marketed in Australia as the weight loss drug Accomplia. It blocks the receptors in the brain where ...
Rimonabant and Progression of Atherosclerosis in Obese Persons
Journal of American Medical Association (subscription), IL - Jul 15, 2008
To the Editor: In the STRADIVARIUS trial, Dr Nissen and colleagues 1 studied the effect of rimonabant on progression of atherosclerosis in patients with ...
Rimonabant and Progression of Atherosclerosis in Obese Persons?Reply Journal of American Medical Association (subscription)
all 2 news articles »
MIMS Summary: NICE approves Acomplia
Healthcare Republic (press release), UK - Jul 29, 2008
NICE has issued final guidance on the use of rimonabant (Acomplia) for the treatment of obesity. Rimonabant is recommended as an adjunct to diet and ...
Turned-off cannabinoid receptor turns on colorectal tumor growth
Hindu, India - Aug 3, 2008
A CB1 antagonist called rimonabant is currently marketed overseas for weight loss. The researchers note that a patient's risk for colorectal cancer should ...
Supersized Problems
Financial Times, UK - Jul 19, 2008
Rimonabant, known by the brand name Acomplia, joins orlistat (Xenical) and sibutramine (Reductil) in the range of weight-loss drugs available from doctors ...
NICE recommends 'suicide risk' drug
Healthcare Republic - Jul 7, 2008
NICE has issued final guidance recommending the use of rimonabant for the treatment of overweight and obese patients, despite concerns that the drug could ...
Sanofi diabetes drug gets European approval
Hays Pharma, UK - Jul 24, 2008
The company last month said the results of a clinical trial had shown its drug rimonabant had significantly improved glucose control in type-two diabetes ...BIT:SANF - SNY
Sanofi-aventis News
PR Newswire (press release), NY - Jul 31, 2008
Positive results from ARPEGGIO, the first clinical trial on the administration of rimonabant to patients with type 2 diabetes not adequately controlled with ...SNY
Sanofi-aventis News
PharmaLive.com (press release), PA - Jul 31, 2008
Positive results from ARPEGGIO, the first clinical trial on the administration of rimonabant to patients with type 2 diabetes not adequately controlled with ...SNY
Discover the Next Generation Treatments and Market Dynamics with ...
MarketWatch - Jul 18, 2008
Sanofi-Aventis' Acomplia (rimonabant) is a first-in-class CB-1 antagonist indicated for the treatment of overweight patients with associated Type 2 diabetes ...
Source: Google News

Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and … -
WP Esler, J Rudolph, TH Claus, W Tang, N Barucci, … - Endocrinology, 2007 - Endocrine Soc
... data on The Endocrine Society?s Journals Online web site at http ... Rimonabant (3
mg/kg) served as a positive control. ... Average SEM = 0.59% (range, 0.26?1.4%). ...

Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model … -
M Ballmaier, M Bortolato, C Rizzetti, M Zoli, G … - Neuropsychopharmacology, 2007 - nature.com
... access provided to Googlebot Access by Web Services. ... F(8,|[thinsp]|60)|[equals]|0.26
NS; post hoc ... Pretreatment with rimonabant at all doses tested significantly ...

Oral Communications
M Pallayova - Diabetic Medicine, 2006 - Blackwell Synergy
... mmol/l (P = 0.001) and in AUC >7.8 (0-480 min) to 0.26 ? 0.09 mmol ... A685 The CB1 blocker
rimonabant reduces liver enzyme levels in overweight/obese people with ...

Clinical diabetes management -
M Pallayova, V Donicova, V Donic, Z Tomori, R … - Blackwell Synergy
... mmol/l (P = 0.001) and in AUC >7.8 (0-480 min) to 0.26 ? 0.09 mmol ... A685 The CB1 blocker
rimonabant reduces liver enzyme levels in overweight/obese people with ...

pr?cis
T Month - The Brown University Child & Adolescent Psychopharmacology …, 2005 - doi.wiley.com
... N EWS N OTES ? Rimonabant shows potential in fighting ... 7771 E-mail: manissescs@manisses.
com Web: www.manisses ... dose 0.37 ? 0.26 mg/kg/day) or methylphenidate (N ...
-

The Hitchhikers Guide to Tobacco Control: a Global Assessment of Harms, Remedies, and Controversies -
RM Davis, M Wakefield, A Amos, PC Gupta - Annual Review of Public Health, 2007 - Annual Reviews
... than the former (0.68 and 0.26 million tons ... Promising new initiatives include
interactive Web-based materials ... prior to cessation) (2), rimonabant (a cannabonoid ...

Metabolic Syndrome: From Global Epidemiology to Individualized Medicine -
JA Batsis, RE Nieto-Martinez, F Lopez-Jimenez - Clinical Pharmacology & Therapeutics, 2007 - nature.com
... a hypocaloric diet with either rimonabant or placebo. 111 This study demonstrated
significant improvements in weight (-6.7 kg), HDL-C (+10.0 mg/dl (0.26 mmol/l ...

A heterozygous gain-of-function mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal …
S Ellard, SE Flanagan, AL Arnold, K Colclough, C … - ingentaconnect.com
Page 1. Orals Basic science orals - Genetics A1 A heterozygous gain-of-function
mutation in the sulphonylurea receptor SUR1 (ABCC8 ...

Orals
S Ellard - Diabetic Medicine, 2006 - Blackwell Synergy
Page 1. Orals Basic science orals - Genetics A1 A heterozygous gain-of-function
mutation in the sulphonylurea receptor SUR1 (ABCC8 ...

Symposium Abstracts
E KANER - Addiction Biology, 2005 - informaworld.com
... The most recent report with Rimonabant from the phase II STRA- TUS ?US ... almost all
are offered using distance learning modes including the Web and continuing ...
-

Source: Google Scholar

Quitting And Keeping The Weight Off With Rimonabant 20 Mg
Using selective cannabinoid 1 (CB1) receptor antagonists such as rimonabant at a dose of 20 mg per day can help people quit smoking, can help them to remain abstinent, and can help prevent the weight gain that so often accompanies attempts at stopping smoking. The lower dose of 5mg, however, was not shown to be effective, according to a Cochrane Systematic Review.
Smoking tobacco sends nicotine into the blood stream, and this chemical disrupts the endocannabinoid system, part of the hormonal control mechanism in the brain that controls energy balance and food intake. Over time the body alters the nature of its energy mechanism to compensate for this effect. Stopping smoking removes the nicotine and once again disturbs the mechanism, adding to the withdrawal symptoms and leaving a person prone to put on weight.

One potential way of preventing this is to take a drug that blocks the receptor that is involved in nicotine's action in the brain -- the cannabinoid 1 receptor. These CB1 receptor antagonists could therefore form part of a therapeutic programme aimed at helping individuals quit smoking, although this drug has not yet been approved as a smoking cessation treatment in the USA or in Europe.

To see whether there was evidence that these receptor antagonists work two Cochrane Researchers, Kate Cahill who works at the Department of Primary Care in the University of Oxford and Michael Ussher who works at St George's, University of London, searched the published and unpublished literature for relevant research projects. They found three trials that involved a total of 1567 smokers and 1661 people who had recently quit smoking. Analysing the data showed that the effect of the drug depended on the dose used:

Quitting with 20mg rimonabant:

People given 20 mg rimonabant increased by 50% their odds of remaining abstinent compared with those on placebo. Smokers who had quit while using 20mg rimonabant increased by 50% their odds of staying abstinent if they continued taking either 5mg or 20mg rimonabant, compared with those who moved to placebo treatment after quitting.
Quitting with 5mg rimonabant:

People who wanted to quit appeared to gain no benefit from 5 mg rimonabant treatment. Furthermore the people who did manage to quit using this lower dose were equally likely to remain abstinent whether they continued with rimonabant treatment or moved to a placebo.

Weight gain:

Weight gain appeared to be significantly lower in people who quit while using 20 mg rimonabant than those taking either 5 mg rimonabant or placebo. The differences in weight between the groups appeared to be maintained through longest follow-up. This beneficial effect was more evident in overweight or obese smokers than in those of normal weight.

"From the preliminary data that we found it appears that 20mg rimonabant may significantly increase a person's likelihood of quitting and may also reduce the amount of weight that they gain," says Cahill.

Source: Jennifer Beal
John Wiley & Sons, Inc.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.